| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
4-Phenyl-7,8-dihydroxycoumarin targets various biochemical pathways relevant to respiratory health and exhibits potential anti-inflammatory and antioxidant activities. It interacts with enzymes and signaling pathways involved in oxidative stress and tumor progression. As a coumarin derivative, it may interact with targets such as cytochrome P450 enzymes, kinases, and proteases. The compound's hydroxyl groups at the 7 and 8 positions contribute to its antioxidant activity through radical scavenging mechanisms. The phenyl ring at position 4 can influence the molecule's lipophilicity and interaction with biological targets, affecting its pharmacological properties. Its potential anticancer properties suggest interactions with pathways regulating cell proliferation and apoptosis.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 4-Phenyl-7,8-dihydroxycoumarin exhibits antioxidant properties through effective radical scavenging. The compound shows potential anti-inflammatory and anticancer activities in various in vitro systems. Its structure allows for interaction with various biological targets, including enzymes and signaling pathways involved in oxidative stress and tumor progression. The presence of hydroxyl groups at the 7 and 8 positions contributes to its antioxidant activity. These in vitro findings support its applications in biomedical research, particularly in oncology and neuroprotection research.
|
| ln Vivo |
In vivo studies of 4-Phenyl-7,8-dihydroxycoumarin are limited as the compound is primarily used as a research chemical. It can be used for bronchiectasis research. The compound's antioxidant and anti-inflammatory properties suggest potential for in vivo evaluation in models of respiratory diseases and oxidative stress. Its potential anticancer properties indicate possible applications in oncology research. However, comprehensive in vivo pharmacological studies specifically targeting this compound are not well documented in the available literature. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 4-Phenyl-7,8-dihydroxycoumarin typically involve testing its antioxidant and anti-inflammatory activities. Antioxidant activity is assessed using cell-free systems such as DPPH radical scavenging assays, ABTS assays, or ferric reducing antioxidant power (FRAP) assays. For anti-inflammatory activity, enzyme assays measuring COX, LOX, or other inflammatory enzymes may be performed. The compound's ability to interact with various biological targets involved in oxidative stress and tumor progression is evaluated. The compound's purity (>98%) and identity are assessed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. All assays are performed with appropriate controls.
|
| Cell Assay |
In vitro cell-based assays for 4-Phenyl-7,8-dihydroxycoumarin involve culturing relevant cell lines to evaluate its antioxidant, anti-inflammatory, and anticancer activities. Cells are treated with varying concentrations of the compound and then exposed to oxidative stress inducers such as H2O2 for antioxidant studies. Reactive oxygen species levels are measured using fluorescent probes. For anti-inflammatory studies, cells are stimulated with inflammatory stimuli and cytokine production is measured by ELISA. For anticancer studies, cancer cell lines are treated with the compound and cell viability is assessed using MTT or similar colorimetric assays. Apoptosis is quantified using flow cytometry with Annexin V/PI staining. All experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for 4-Phenyl-7,8-dihydroxycoumarin would be conducted to evaluate its antioxidant, anti-inflammatory, and anticancer activities. For bronchiectasis research, animal models of respiratory diseases would be used. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. For antioxidant studies, animals would be administered the compound and markers of oxidative stress measured. For anticancer studies, tumor-bearing animals would be treated and tumor growth monitored. Parameters assessed would include body weight, organ weights, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 4-Phenyl-7,8-dihydroxycoumarin reflect its nature as a small coumarin derivative. It has a molecular weight of 254.24 and the molecular formula C15H10O4. The phenyl ring at position 4 influences the molecule's lipophilicity, which may affect its absorption and distribution. As a coumarin, it would have moderate lipophilicity that facilitates absorption and distribution. The compound is expected to be metabolized through standard xenobiotic pathways in the liver, including cytochrome P450-mediated oxidation and conjugation reactions. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 4-Phenyl-7,8-dihydroxycoumarin has been evaluated in the context of its use as a research chemical. As a coumarin derivative, it may have biological activities that should be carefully evaluated. Coumarins can have anticoagulant effects and may cause liver toxicity at high doses. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile. No clinical development has been reported for this compound.
|
| References |
[1]. A kind of Chinese medicine and western medicine combination for treating bronchiectasiss and preparation method thereof. Patent CN106491853
|
| Additional Infomation |
According to reports, ironwood contains 7,8-dihydroxy-4-phenyl-2H-chromene-2-one, and there is relevant data.
4-Phenyl-7,8-dihydroxycoumarin (CAS# 842-01-3) is also known as 7,8-dihydroxy-4-phenyl-2H-chromen-2-one and 7,8-dihydroxy-4-phenylcoumarin. It has the molecular formula C15H10O4 and a molecular weight of 254.24. The compound is a coumarin derivative used for bronchiectasis research. It exhibits antioxidant and potential anticancer properties. The presence of hydroxyl groups at the 7 and 8 positions contributes to its antioxidant activity. The phenyl ring at position 4 influences lipophilicity and biological target interactions. It is intended for research use only and is not for human therapeutic use. |
| Molecular Formula |
C15H10O4
|
|---|---|
| Molecular Weight |
254.24
|
| Exact Mass |
254.057
|
| CAS # |
842-01-3
|
| PubChem CID |
5413034
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
495.1±45.0 °C at 760 mmHg
|
| Melting Point |
190-195ºC(lit.)
|
| Flash Point |
193.8±22.2 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.699
|
| LogP |
3.56
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
384
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C=C(C2C=CC=CC=2)C2C(=C(C(=CC=2)O)O)O1
|
| InChi Key |
JRVIIPJSVKTPBK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O4/c16-12-7-6-10-11(9-4-2-1-3-5-9)8-13(17)19-15(10)14(12)18/h1-8,16,18H
|
| Chemical Name |
7,8-dihydroxy-4-phenylchromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (393.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9333 mL | 19.6665 mL | 39.3329 mL | |
| 5 mM | 0.7867 mL | 3.9333 mL | 7.8666 mL | |
| 10 mM | 0.3933 mL | 1.9666 mL | 3.9333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
